Other studies regarding upstream regulators of SIRT1, such as IRF9/PPAR-α, NAMPT/NMNAT, HuR, AMPK, PARP1, CK2 and cathepsins have pointed to these proteins as possible therapeutic targets for the treatment of various inflammatory pathologies, including liver diseases. This evidence concerns the gene PARP1 and liver disorder.